Solid Tumors
See how Bayer is investigating solid tumors across the pipeline
Follow the connections from areas of research to investigational compounds and the clinical trials evaluating them.
Solid Tumors Overview
Bayer’s solid tumor research spans multiple molecular targets and signaling pathways, including HER2, KEAP1-NRF2, RAS-PI3Kα, and PRMT5.
Together, these programs represent distinct scientific approaches being investigated across solid tumors, connecting areas of research with compounds in development and their related clinical trials.
6 investigational compounds
7 areas of research
10 clinical trials
Clinical Trials
Tumor Type(s) | Phase | Status | Description | NCT Number |
|---|---|---|---|---|
Lung Cancer, Solid Tumors, Head and Neck Cancer | I | Now Enrolling | A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors | |
Solid Tumors | I | Now Enrolling | A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | |
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Pancreatic) | I | Now Enrolling | Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors | |
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Pancreatic) | I | Now Enrolling | A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors | |
Solid Tumors | I | Now Enrolling | A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS G12D Mutation | |
Solid Tumors | I, II | Now Enrolling | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors | |
Solid Tumors | I, II | Active, Not Enrolling | A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors | |
Solid Tumors | II | Now Enrolling | A Phase 2 Open-Label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-Activating Mutations | |
Solid Tumors | Non-interventional Study | Now Enrolling | Prospective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib | |
Solid Tumors | Non-interventional Study | Now Enrolling | Special Drug Use Investigation for Larotrectinib |
Bayer’s Oncology Pipeline Brochure
Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.
The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.
HER2, human epidermal growth factor receptor 2; KEAP1, Kelch-like ECH-associated protein 1; KRAS-G12C, Kirsten rat sarcoma viral oncogene homolog with a glycine-to-cysteine substitution at codon 12; KRAS-G12D, Kirsten rat sarcoma viral oncogene homolog with a glycine-to-aspartic acid substitution at codon 12; MAPK, mitogen-activated protein kinase; MTAP, methylthioadenosine phosphorylase; NRF2, nuclear factor erythroid 2–related factor 2; PI3Kα, phosphatidylinositol 3-kinase alpha; PRMT5, protein arginine methyltransferase 5; RAS, rat sarcoma; SOS1, son of sevenless homolog 1; TRK, tropomyosin receptor kinase; WRN, Werner syndrome protein.